




RealRate

PHARMACEUTICAL 2021

Arcutis Biotherapeutics Inc.
Rank 224 of 409



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2021

Arcutis Biotherapeutics Inc. Rank 224 of 409

The relative strengths and weaknesses of Arcutis Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcutis Biotherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 232% points. The greatest weakness of Arcutis Biotherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -155%, being 199% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	292,826
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,602
Liabilities, Non-Current	5,046
Other Assets	3,427
Other Compr. Net Income	-1.0
Other Expenses	0
Other Liabilities	0
Other Net Income	967
Property and Equipment	2,016
Research and Development	115,308
Revenues	0
Selling, General and Administrative Expense	21,337

Output Variable	Value in 1000 USD
Assets	298,269
Liabilities	27,648
Expenses	136,645
Stockholders Equity	270,621
Net Income	-135,678
Comprehensive Net Income	-135,678
Economic Capital Ratio	-155%

